# US 2020/0002428 A1 · Treatment of c1013g/cxcr4-associated waldenstrom's macroglobulinemia with an anti-cxcr4 antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002428 A1
- Document ID: US20200002428A1
- Status: Published application
- Kind: A1
- Application number: 16/271,569
- Filed: 2019-02-08
- Published: 2020-01-02
- Earliest claimed: 2013-11-06
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Irene M. Ghobrial; Aldo M. Roccaro; Josephine M. Cardarelli; Antonio Sacco
- Web page: https://patentgrep.com/patent/US20200002428A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/572: {cytotoxic response}
- C07K 14/7158: {for chemokines}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides a method for treating a subject afflicted with Waldenström's macroglobulinemia (WM) comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to a CXCR4 receptor expressed on the surface of a WM cell. The disclosure also provides a therapeutic regimen for treating a patient afflicted with C1013G/CXCR4-associated WM.

## Claims

### Claim 1

A method for treating a subject afflicted with C1013G/CXCR4-associated Waldenström's macroglobulinemia comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to a C-X-C chemokine receptor type 4 (CXCR4) receptor expressed on the surface of a Waldenström's macroglobulinemia cell.

### Claim 2

A method for treating a subject afflicted with C1013G/CXCR4-associated Waldenström's macroglobulinemia, which method comprises:
(a) selecting a subject that is a suitable candidate for treatment, the selecting comprising:
(i) assessing whether cells in a test tissue sample obtained from Waldenström's macroglobulinemia tissue in the subject carry the C1013G mutation in the C-X-C chemokine receptor type 4 (CXCR4) gene; and
(ii) selecting the subject as a suitable candidate based on a determination that the Waldenström's macroglobulinemia cells carry the C1013G mutation in the CXCR4 gene; and
(b) administering to the selected subject a therapeutically effective amount of an anti-CXCR4 antibody or an antigen-binding portion thereof that specifically binds to a CXCR4 receptor expressed on the surface of a C1013G/CXCR4-associated Waldenström's macroglobulinemia cell.

### Claim 3

A method for treating a subject afflicted with C1013G/CXCR4-associated Waldenström's macroglobulinemia, which method comprises administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to a C-X-C chemokine receptor type 4 (CXCR4) receptor expressed on the surface of a C1013G/CXCR4-associated Waldenström's macroglobulinemia cell, the subject having been selected on the basis that the Waldenström's macroglobulinemia cells of the subject are determined to carry the C1013G mutation in the CXCR4 gene.

### Claim 4 (depends on 2)

The method of claim 2, wherein:
(a) the subject is a human and the anti-CXCR4 antibody or antigen-binding portion thereof binds to a human CXCR4 receptor carrying the C1013G mutation;
(b) the anti-CXCR4 antibody or antigen-binding portion thereof is of a human IgG1, IgG2 or IgG4 isotype;
(c) the anti-CXCR4 antibody or antigen-binding portion thereof is a monoclonal antibody or an antigen-binding portion thereof;
(d) the anti-CXCR4 antibody or antigen-binding portion thereof is a chimeric, humanized or human antibody or an antigen-binding portion thereof; and/or
(e) the anti-CXCR4 antibody or antigen-binding portion thereof induces apoptosis of a C1013G/CXCR4-expressing cell.

### Claim at position 5

5-9. (canceled)

### Claim 10 (depends on 2)

The method of claim 2, wherein the anti-CXCR4 antibody or antigen-binding portion thereof is administered as monotherapy.

### Claim 11 (depends on 2)

The method of claim 2, wherein the anti-CXCR4 antibody or antigen-binding portion thereof inhibits the activity of the C1013G/CXCR4 receptor and increases sensitivity of the Waldenström's macroglobulinemia cell to an anti-cancer agent.

### Claim 12 (depends on 2)

The method of claim 2, further comprising administering at least one anti-cancer agent in combination with the anti-CXCR4 antibody or antigen-binding portion thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the at least one anti-cancer agent is ibrutinib, bortezomib, carfilzomib, idelalisib, panobinostat, dexamethasone, rituximab, thalidomide, cyclophosphamide, lenalidomide, doxorubicin, vincristine, prednisone, fludarabine, chlorambucil, bendamustine, cladribine, alemtuzumab, ofatumumab, everolimus, cisplatin, bleomycin sulfate, carmustine, mitoxantrone, etoposide, cytarabine, ifosfamide, and carboplatin.

### Claim 14 (depends on 12)

The method of claim 12, wherein the at least one anti-cancer agent is ibrutinib.

### Claim 15 (depends on 2)

The method of claim 2, wherein the anti-CXCR4 antibody or antigen-binding portion thereof is administered to the subject after failure of a prior treatment for Waldenström's macroglobulinemia.

### Claim 16 (depends on 15)

The method of claim 15, wherein the prior treatment is with an agent selected from a mammalian target of rapamycin (mTOR) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and phosphatidylinositol 3-kinase (PI3K) inhibitor.

### Claim 17 (depends on 15)

The method of claim 15, wherein the prior treatment is:
(a) first-line treatment with ibrutinib;
(b) first-line treatment with a BDR (bortezomib, dexamethasone and rituximab) regimen and second-line treatment with ibrutinib; or
(c) first-line treatment with a RCD (cyclophosphamide, dexamethasone and rituximab) regimen and second-line treatment with ibrutinib.

### Claim 18

(canceled)

### Claim 19 (depends on 2)

The method of claim 2, wherein the anti-CXCR4 antibody or portion thereof comprises a heavy chain variable region CDR1 comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 1, a heavy chain variable region CDR2 comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 5, a heavy chain variable region CDR3 comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 9, a light chain variable region CDR1 comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 13, a light chain variable region CDR2 comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 17, and a light chain variable region CDR3 comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 21.

### Claim 20 (depends on 2)

The method of claim 2, wherein the anti-CXCR4 antibody or portion thereof comprises:
(a) a heavy chain variable region comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 25, and a light chain variable region comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 29; or
(b) a heavy chain variable region comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 41, and a light chain variable region comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 45.

### Claim 21

(canceled)

### Claim 22 (depends on 2)

The method of claim 2, wherein the anti-CXCR4 antibody is ulocuplumab.

### Claim 23 (depends on 2)

The method of claim 2, wherein the anti-CXCR4 antibody or portion thereof:
(a) cross-competes for binding to human CXCR4 with an antibody which comprises a heavy chain variable region comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 25, and a light chain variable region comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 29; and/or
(b) binds to the same epitope region on CXCR4 as does an antibody which comprises a heavy chain variable region comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 25, and a light chain variable region comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 29.

### Claim 24

(canceled)

### Claim 25 (depends on 2)

The method of claim 2, wherein the therapeutically effective amount of the anti-CXCR4 antibody or antigen-binding portion thereof:
(a) comprises a dose ranging from 0.1 to 20 mg/kg body weight;
(b) comprises a dose of 0.1, 0.3, 0.5, 1, 3, 5, 10 or 20 mg/kg body weight; and/or
(c) is 3 or 10 mg/kg body weight.

### Claim at position 22

26-27. (canceled)

### Claim 28 (depends on 26)

The method of claim 26, wherein the anti-CXCR4 antibody or antigen-binding portion thereof is administered at a dosing schedule of once per week, once every two weeks, once every three weeks, or once a month.

### Claim 29

(canceled)

### Claim 30 (depends on 2)

The method of claim 2, wherein the anti-CXCR4 antibody or antigen-binding portion thereof is administered via intravenous or subcutaneous administration.

### Claim 31 (depends on 2)

The method of claim 2, wherein the therapeutically effective amount of the antibody or antigen-binding portion thereof comprises a fixed dose.

### Claim 32 (depends on 31)

The method of claim 31, wherein the fixed dose is:
(a) 350, 750 or 1500 mg;
(b) administered in a dosing schedule of once per week, once every two weeks, or once every three weeks; and/or
(c) administered in a dosing schedule of once every 7 days or once every 14 days.

### Claim at position 28

33-34. (canceled)

### Claim 35 (depends on 14)

The method of claim 14, wherein ibrutinib is administered at a dose of 420 mg orally once a day.

### Claim 36 (depends on 2)

The method of claim 2, wherein the C1013G mutation is detected by a polymerase chain reaction (PCR) assay, a reverse transcriptase-polymerase chain reaction (RT-PCR) assay, a nucleic acid hybridization assay, or by DNA sequencing.

### Claim 37 (depends on 36)

The method of claim 36, wherein:
(a) the PCR assay is a real-time allele-specific PCR (AS-PCR) assay; and/or
(b) the DNA sequencing is whole genome DNA sequencing.

### Claim 38

(canceled)

### Claim 39

A method for selecting a Waldenström's macroglobulinemia patient for treatment with an antibody or an antigen-binding portion thereof that specifically binds to a C-X-C chemokine receptor type 4 (CXCR4) receptor expressed on the surface of a Waldenström's macroglobulinemia cell, which method comprises:
(a) assessing whether cells in a test tissue sample obtained from a Waldenström's macroglobulinemia patient carry the C1013G mutation in the CXCR4 gene; and
(b) selecting the patient for treatment based on a determination that the Waldenström's macroglobulinemia cells carry the C1013G mutation in the CXCR4 gene.

### Claim at position 34

40-41. (canceled)

### Claim 42 (depends on 2)

A kit for treating C1013G/CXCR4-associated Waldenström's macroglobulinemia in a subject, the kit comprising:
(a) one or more doses of an anti-CXCR4 antibody or an antigen-binding portion thereof; and
(b) instructions for using the anti-CXCR4 antibody in the method of claim 2.
